600671 Hangzhou Tianmushan Pharmaceutical Enterprise
- 7.72
- -0.25-3.14%
Hangzhou Tianmushan Pharmaceutical Enterprise News
Announcement of Hangzhou Tianmushan Pharmaceutical Co., Ltd. on the completion of the board of directors, the supervisory board election, and the appointment of senior management and securities affairs representatives.
Announcement of the Revision of the Articles of Association of Hangzhou Tianmushan Pharmaceutical Co., Ltd.
Amendment to the Articles of Association of Hangzhou Tianmushan Pharmaceutical Co., Ltd.
Notice of the Fourth Extraordinary Shareholders' Meeting of Hangzhou Tianmushan Pharmaceutical Co., Ltd. to be held in 2024.
Announcement of the resolution of the third extraordinary general meeting of shareholders of Hangzhou Tianmu Mountain Pharmaceutical Co., Ltd. in 2024.
Legal opinion of Shanghai Zechang Law Firm on the 2024 third interim shareholders' meeting of Hangzhou Tianmushan Pharmaceutical Co., Ltd.
Announcement from Hangzhou Tianmu Shan Pharmaceutical Joint Stock Co., Ltd. regarding the cancellation of the risk warning for delisting of the company's stocks and continuation of other risk warnings, as well as the suspension of trading.
Announcement from Hangzhou Tianmushan Pharmaceutical Co., Ltd. regarding the election of the twelfth supervisory board employee representative supervisor.
Announcement of resolutions made during the second extraordinary shareholders meeting of Hangzhou Tianmushan Pharmaceutical Co., Ltd. in 2024.
Legal opinion of Shanghai Zechang Law Firm on the second extraordinary general meeting of shareholders of Hangzhou Tianmushan Pharmaceutical Co., Ltd. in 2024.
Announcement on the Reply to the Inquiry Letter of the 2023 Annual Report by Hangzhou Tianmu Mountain Pharmaceutical Co., Ltd. to the Shanghai Stock Exchange.
2024 Third Extraordinary Shareholders' Meeting Materials of Hangzhou Tianmushan Pharmaceutical Co., Ltd.
Hangzhou Tianmu Mountain Pharmaceutical Co., Ltd. 2024 Second Extraordinary Shareholders' Meeting Materials.
Notice of Hangzhou Tianmusan Pharmaceutical Co., Ltd. on convening the 3rd Extraordinary General Meeting of Shareholders in 2024
Announcement of Hangzhou Tianmusan Pharmaceutical Co., Ltd. on the election of the board of directors and board of supervisors for a new term
Announcement of Hangzhou Tianmusan Pharmaceutical Co., Ltd. on postponing the response to the Shanghai Stock Exchange's inquiry letter on the disclosure of information disclosure of the company's 2023 annual report
Notice of Hangzhou Tianmusan Pharmaceutical Co., Ltd. on convening the 2nd Extraordinary General Meeting of Shareholders in 2024
Announcement of Hangzhou Tianmusan Pharmaceutical Co., Ltd. on the implementation of production capacity improvement and technological transformation projects by its wholly-owned subsidiary Huangshan Tianmu Pharmaceutical Co., Ltd.
Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders of Hangzhou Tianmushan Pharmaceutical Co., Ltd.
Legal Opinion of Shanghai Zechang Law Firm on the 2023 Annual General Meeting of Shareholders of Hangzhou Tianmusan Pharmaceutical Co., Ltd.
Analysis
Price Target
No Data
